HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.79
−8.73%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$34.50
From 52W high−21.16%
Volume983105.00
Market cap$1.97B
P/E (TTM)10.8x
P/S (TTM)2.1x
Div yield—
Key dataNov 4, 2026
Open
$34.50
From 52W high
−21.16%
Volume
983105.00
Market cap
$1.97B
ValuationView details →
P/E (Fwd)
8.5x
EV/EBITDA
5.3x
P/E (TTM)
10.8x
RSI (14)
46.2
MomentumView details →
1D Return
−8.73%
YTD Return
+1.28%
SummaryUpdated Jun 1, 2026
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company founded in 2017 and based in Plymouth Meeting, Pennsylvania. The company went public in August 2020 and has established itself as a profitable biotechnology firm focused exclusively on developing and commercializing therapies for patients with rare neurological disorders. Since its founding, Harmony has built a robust pipeline of eight assets across three distinct therapeutic franchises, with its flagship product WAKIX generating over $2 billion in cumulative sales since launch.
Similar companies
Latest newsMore news →
Harmony Biosciences reported quarterly earnings of $0.81 per share, down from $0.87 per share a year earlier and below the $1 Zacks Investment Research, Inc. consensus estimate.2h agoHarmony Biosciences Holdings, Inc. shares fell 5.7% in premarket trading.4h agoHarmony Biosciences Holdings, Inc. shares fell Monday following the CEO transition announcement.23d ago